Published in J Clin Oncol on November 01, 2005
Behavioral symptoms in patients with breast cancer and survivors. J Clin Oncol (2008) 2.38
Meta-analysis of cognitive functioning in breast cancer survivors previously treated with standard-dose chemotherapy. J Clin Oncol (2012) 2.33
Cancer- and cancer treatment-associated cognitive change: an update on the state of the science. J Clin Oncol (2012) 1.99
Cognitive function in breast cancer patients prior to adjuvant treatment. Breast Cancer Res Treat (2007) 1.95
One-year outcomes of a behavioral therapy intervention trial on sleep quality and cancer-related fatigue. J Clin Oncol (2009) 1.81
Systemic 5-fluorouracil treatment causes a syndrome of delayed myelin destruction in the central nervous system. J Biol (2008) 1.71
Effects of tamoxifen and raloxifene on memory and other cognitive abilities: cognition in the study of tamoxifen and raloxifene. J Clin Oncol (2009) 1.54
A prospective longitudinal study of chemotherapy-induced cognitive changes in breast cancer patients. Support Care Cancer (2010) 1.40
Prevalence, mechanisms, and management of cancer-related cognitive impairment. Int Rev Psychiatry (2014) 1.30
Assessing cognitive function in cancer patients. Support Care Cancer (2006) 1.25
Cytokine genetic variations and fatigue among patients with breast cancer. J Clin Oncol (2013) 1.21
Cognitive functioning in breast cancer survivors: a controlled comparison. Cancer (2009) 1.20
Effect of medical Qigong on cognitive function, quality of life, and a biomarker of inflammation in cancer patients: a randomized controlled trial. Support Care Cancer (2011) 1.19
A randomised, placebo-controlled, double-blind trial of the effects of d-methylphenidate on fatigue and cognitive dysfunction in women undergoing adjuvant chemotherapy for breast cancer. Support Care Cancer (2007) 1.13
Brain vulnerability to chemotherapy toxicities. Psychooncology (2012) 1.11
Pre-chemotherapy differences in visuospatial working memory in breast cancer patients compared to controls: an FMRI study. Front Hum Neurosci (2011) 1.08
Predictors and course of chronic fatigue in long-term breast cancer survivors. J Cancer Surviv (2010) 0.98
Fatigue after treatment in breast cancer survivors: prevalence, determinants and impact on health-related quality of life. Support Care Cancer (2011) 0.97
What do perceived cognitive problems reflect? J Support Oncol (2008) 0.96
Cognitive functioning after cancer treatment: a 3-year longitudinal comparison of breast cancer survivors treated with chemotherapy or radiation and noncancer controls. Cancer (2011) 0.95
Quality of life over time in women diagnosed with ductal carcinoma in situ, early-stage invasive breast cancer, and age-matched controls. Breast Cancer Res Treat (2012) 0.93
Prolonged impact of chemotherapy on fatigue in breast cancer survivors: a longitudinal comparison with radiotherapy-treated breast cancer survivors and noncancer controls. Cancer (2011) 0.93
Altered cerebral blood flow one month after systemic chemotherapy for breast cancer: a prospective study using pulsed arterial spin labeling MRI perfusion. PLoS One (2014) 0.91
Patterns of change in cognitive function with anastrozole therapy. Cancer (2015) 0.91
A comparison of cognitive function, sleep and activity levels in disease-free breast cancer patients with or without cancer-related fatigue syndrome. BMJ Support Palliat Care (2012) 0.91
Factors associated with cancer-related fatigue in breast cancer patients undergoing endocrine therapy in an urban setting: a cross-sectional study. BMC Cancer (2010) 0.89
Opening up the window into "chemobrain": a neuroimaging review. Sensors (Basel) (2013) 0.89
Effect of exercise in reducing breast and chest-wall pain in patients with breast cancer: a pilot study. Curr Oncol (2012) 0.87
Prevalence of fatigue among cancer patients receiving various anticancer therapies and its impact on quality of life: a cross-sectional study. Indian J Palliat Care (2012) 0.85
Does cognitive impairment after chemotherapy for breast cancer improve over time or does practice make perfect? J Clin Oncol (2006) 0.85
Quantifying fatigue in (long-term) colorectal cancer survivors: a study from the population-based patient reported outcomes following initial treatment and long term evaluation of survivorship registry. Eur J Cancer (2013) 0.85
A prospective study of grey matter and cognitive function alterations in chemotherapy-treated breast cancer patients. Springerplus (2014) 0.83
Cognitive function in older women with breast cancer treated with standard chemotherapy and capecitabine on Cancer and Leukemia Group B 49907. Breast Cancer Res Treat (2013) 0.82
Subjective cognitive complaints one year after ceasing adjuvant endocrine treatment for early-stage breast cancer. Br J Cancer (2012) 0.82
Associations between adjuvant endocrine therapy and onset of physical and emotional concerns among breast cancer survivors. Support Care Cancer (2013) 0.82
Cognitive function in breast cancer survivors compared to healthy age- and education-matched women. Clin Neuropsychol (2009) 0.81
Biomarkers of fatigue related to adjuvant chemotherapy for breast cancer: evaluation of plasma and lymphocyte expression. Clin Transl Med (2015) 0.80
Long-term cognitive function change among breast cancer survivors. Breast Cancer Res Treat (2014) 0.79
Multivariate analysis of brain metabolism reveals chemotherapy effects on prefrontal cerebellar system when related to dorsal attention network. EJNMMI Res (2013) 0.79
The relationship of cognitive performance to concurrent symptoms, cancer- and cancer-treatment-related variables in women with early-stage breast cancer: a 2-year longitudinal study. J Cancer Res Clin Oncol (2016) 0.79
Interventions to Alleviate Symptoms Related to Breast Cancer Treatments and Areas of Needed Research. J Cancer Sci Ther (2011) 0.78
Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancer. Br J Cancer (2007) 0.78
Preserved learning and memory following 5-fluorouracil and cyclophosphamide treatment in rats. Pharmacol Biochem Behav (2011) 0.77
Topological Organization of Metabolic Brain Networks in Pre-Chemotherapy Cancer with Depression: A Resting-State PET Study. PLoS One (2016) 0.75
Is symptom-oriented follow-up still up to date? Breast Care (Basel) (2013) 0.75
Long-term cognitive impairment in older adult twins discordant for gynecologic cancer treatment. J Gerontol A Biol Sci Med Sci (2011) 0.75
Can physical activity help to maintain cognitive functioning and psychosocial well-being among breast cancer patients treated with chemotherapy? A randomised controlled trial: study protocol. BMC Public Health (2015) 0.75
The Working Memory and Dorsolateral Prefrontal-Hippocampal Functional Connectivity Changes in Long-Term Survival Breast Cancer Patients Treated with Tamoxifen. Int J Neuropsychopharmacol (2017) 0.75
Postoperative hormonal therapy prevents recovery of neurological damage after surgery in patients with breast cancer. Sci Rep (2016) 0.75
A prospective study of changes in anxiety, depression, and problems in living during chemotherapy treatments: effects of age and gender. Support Care Cancer (2017) 0.75
Asiatic acid protects against cognitive deficits and reductions in cell proliferation and survival in the rat hippocampus caused by 5-fluorouracil chemotherapy. PLoS One (2017) 0.75
Delivering affordable cancer care in high-income countries. Lancet Oncol (2011) 12.79
Drug penetration in solid tumours. Nat Rev Cancer (2006) 9.80
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol (2008) 7.89
Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst (2007) 7.10
Repopulation of cancer cells during therapy: an important cause of treatment failure. Nat Rev Cancer (2005) 3.58
Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. J Clin Oncol (2011) 3.46
A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. Clin Cancer Res (2007) 3.41
Factors associated with failure to publish large randomized trials presented at an oncology meeting. JAMA (2003) 3.36
Treatment of prostate cancer with intermittent versus continuous androgen deprivation: a systematic review of randomized trials. J Clin Oncol (2013) 2.92
Cytokines and their relationship to the symptoms and outcome of cancer. Nat Rev Cancer (2008) 2.89
Up-front use of aromatase inhibitors as adjuvant therapy for breast cancer: the emperor has no clothes. J Clin Oncol (2009) 2.66
Androgen receptor expression and outcomes in early breast cancer: a systematic review and meta-analysis. J Natl Cancer Inst (2013) 2.54
The distribution of the anticancer drug Doxorubicin in relation to blood vessels in solid tumors. Clin Cancer Res (2005) 2.33
Placebo effects in oncology. J Natl Cancer Inst (2003) 2.23
New therapies for castration-resistant prostate cancer: efficacy and safety. Eur Urol (2011) 2.21
Potential drug interactions and duplicate prescriptions among cancer patients. J Natl Cancer Inst (2007) 2.14
When are "positive" clinical trials in oncology truly positive? J Natl Cancer Inst (2010) 2.09
The price we pay for progress: a meta-analysis of harms of newly approved anticancer drugs. J Clin Oncol (2012) 1.98
Simple prognostic score for metastatic castration-resistant prostate cancer with incorporation of neutrophil-to-lymphocyte ratio. Cancer (2014) 1.93
Disseminated intravascular coagulation as the presenting sign of metastatic prostate cancer. J Gen Intern Med (2006) 1.88
Drug resistance in metastatic castration-resistant prostate cancer. Nat Rev Clin Oncol (2010) 1.86
Screening trials are even more difficult than we thought they were. J Natl Cancer Inst (2002) 1.76
MRI monitoring of intratumoral drug delivery and prediction of the therapeutic effect with a multifunctional thermosensitive liposome. Biomaterials (2011) 1.71
Evaluation of cognitive function associated with chemotherapy: a review of published studies and recommendations for future research. J Clin Oncol (2007) 1.69
Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer. J Clin Oncol (2003) 1.63
Infarct size, ejection fraction, and mortality in diabetic patients with acute myocardial infarction treated with thrombolytic therapy. Am Heart J (2007) 1.62
Evaluating the value of number of cycles of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer. Eur Urol (2011) 1.62
Reassessment of deferrals for tattooing and piercing. Transfusion (2009) 1.61
The penetration of anticancer drugs through tumor tissue as a function of cellular adhesion and packing density of tumor cells. Cancer Res (2006) 1.58
Improved results of induction chemoradiation before surgical intervention for selected patients with stage IIIA-N2 non-small cell lung cancer. J Thorac Cardiovasc Surg (2007) 1.58
Trials in palliative treatment--have the goal posts been moved? Lancet Oncol (2008) 1.57
The association between radiographic response and overall survival in men with metastatic castration-resistant prostate cancer receiving chemotherapy. Cancer (2011) 1.55
Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts. Cancer Res (2005) 1.48
Current incidence and estimated residual risk of transfusion-transmitted infections in donations made to Canadian Blood Services. Transfusion (2007) 1.47
The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant. Br J Haematol (2004) 1.45
The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival. Eur J Cancer (2009) 1.45
Oncogenic targets, magnitude of benefit, and market pricing of antineoplastic drugs. J Clin Oncol (2011) 1.43
Effect of platelet additive solution on bacterial dynamics and their influence on platelet quality in stored platelet concentrates. Transfusion (2010) 1.42
Mathematics in the realm of lapatinib: 500 + 500 = 1,500? J Clin Oncol (2008) 1.42
Company stock prices before and after public announcements related to oncology drugs. J Natl Cancer Inst (2011) 1.42
Extramedullary infiltrates of AML are associated with CD56 expression, 11q23 abnormalities and inferior clinical outcome. Leuk Res (2004) 1.42
ASCO core values. J Clin Oncol (2006) 1.40
Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy. Urol Oncol (2010) 1.31
Evolution of clinical trial design in early drug development: systematic review of expansion cohort use in single-agent phase I cancer trials. J Clin Oncol (2013) 1.28
Preclinical development of molecular-targeted agents for cancer. Nat Rev Clin Oncol (2010) 1.27
Abiraterone in Metastatic Prostate Cancer. N Engl J Med (2017) 1.27
Management of advanced prostate cancer after first-line chemotherapy. J Clin Oncol (2005) 1.26
Assessing cognitive function in cancer patients. Support Care Cancer (2006) 1.25
Evolution of the randomized controlled trial in oncology over three decades. J Clin Oncol (2008) 1.25
Addition of bevacizumab to chemotherapy for treatment of solid tumors: similar results but different conclusions. J Clin Oncol (2010) 1.22
Sorafenib for metastatic renal cancer: the Princess Margaret experience. Am J Clin Oncol (2008) 1.22
Perioperative chemotherapy for muscle-invasive bladder cancer: A population-based outcomes study. Cancer (2014) 1.19
Development of renal disease in people at high cardiovascular risk: results of the HOPE randomized study. J Am Soc Nephrol (2003) 1.18
Reporting of serious adverse drug reactions of targeted anticancer agents in pivotal phase III clinical trials. J Clin Oncol (2010) 1.18
Poor correlation between progression-free and overall survival in modern clinical trials: are composite endpoints the answer? Eur J Cancer (2011) 1.16
Evaluation of treatment benefit: randomized controlled trials and population-based observational research. J Clin Oncol (2013) 1.15
Differential methylation of cell-free circulating DNA among patients with pancreatic cancer versus chronic pancreatitis. Cancer (2010) 1.14
Intermittent androgen blockade should be regarded as standard therapy in prostate cancer. Nat Clin Pract Oncol (2008) 1.14
The distribution of the therapeutic monoclonal antibodies cetuximab and trastuzumab within solid tumors. BMC Cancer (2010) 1.14
A randomised, placebo-controlled, double-blind trial of the effects of d-methylphenidate on fatigue and cognitive dysfunction in women undergoing adjuvant chemotherapy for breast cancer. Support Care Cancer (2007) 1.13
Chemotherapy-based treatment for castration-resistant prostate cancer. J Clin Oncol (2011) 1.11
Declining hepatitis C rates in first-time blood donors: insight from surveillance and case-control risk factor studies. Transfusion (2008) 1.11
Donor understanding and attitudes about current and potential deferral criteria for high-risk sexual behavior. Transfusion (2011) 1.11
Compendium of unpublished phase III trials in oncology: characteristics and impact on clinical practice. J Clin Oncol (2011) 1.10
Scheduling of radiation and chemotherapy for limited-stage small-cell lung cancer: repopulation as a cause of treatment failure? J Clin Oncol (2006) 1.08
Clinical relevance of cytogenetic abnormalities at diagnosis of acquired aplastic anaemia in adults. Br J Haematol (2006) 1.07
The prognostic importance of metastatic site in men with metastatic castration-resistant prostate cancer. Eur Urol (2013) 1.07
Ethics in oncology: consulting for the investment industry. J Clin Oncol (2007) 1.06
Randomized feasibility study of de-escalated (every 12 wk) versus standard (every 3 to 4 wk) intravenous pamidronate in women with low-risk bone metastases from breast cancer. Am J Clin Oncol (2013) 1.05
Statistical power of negative randomized controlled trials presented at American Society for Clinical Oncology annual meetings. J Clin Oncol (2007) 1.05
Validation and implementation of a new hemoglobinometer for donor screening at Canadian Blood Services. Transfusion (2012) 1.03
Reversal of ATP-binding cassette drug transporter activity to modulate chemoresistance: why has it failed to provide clinical benefit? Cancer Metastasis Rev (2013) 1.03
The role of systemic chemotherapy in the management of muscle-invasive bladder cancer. Lancet Oncol (2002) 1.01
Influence of concurrent medications on outcomes of men with prostate cancer included in the TAX 327 study. Can Urol Assoc J (2013) 1.00
Does the incidence and outcome of brain metastases in locally advanced non-small cell lung cancer justify prophylactic cranial irradiation or early detection? Lung Cancer (2005) 1.00
Tolerability of the Intergroup 0099 (INT 0099) regimen in locally advanced nasopharyngeal cancer with a focus on patients' nutritional status. Int J Radiat Oncol Biol Phys (2004) 0.98
Cognitive function, fatigue, and menopausal symptoms in breast cancer patients receiving adjuvant chemotherapy: evaluation with patient interview after formal assessment. Psychooncology (2006) 0.98
Targeting tumor architecture to favor drug penetration: a new weapon to combat chemoresistance in pancreatic cancer? Cancer Cell (2012) 0.96
Quality of abstracts describing randomized trials in the proceedings of American Society of Clinical Oncology meetings: guidelines for improved reporting. J Clin Oncol (2004) 0.96
The influence of P-glycoprotein expression and its inhibitors on the distribution of doxorubicin in breast tumors. BMC Cancer (2009) 0.95
Epidemiology of hepatitis B in Canadian blood donors. Transfusion (2008) 0.94
Screening of Canadian Blood Services donors for severe immunoglobulin A deficiency. Transfusion (2010) 0.94
Concurrent and sequential administration of chemotherapy and the Mammalian target of rapamycin inhibitor temsirolimus in human cancer cells and xenografts. Clin Cancer Res (2009) 0.94
The tumor microenvironment and strategies to improve drug distribution. Front Oncol (2013) 0.93
A phase II trial of continuous low-dose oral cyclophosphamide and celecoxib in patients with renal cell carcinoma. Cancer Chemother Pharmacol (2006) 0.93
Progression of renal insufficiency in type 2 diabetes with and without microalbuminuria: results of the Heart Outcomes and Prevention Evaluation (HOPE) randomized study. Am J Kidney Dis (2003) 0.91
Reduction of intracellular pH as a strategy to enhance the pH-dependent cytotoxic effects of melphalan for human breast cancer cells. Clin Cancer Res (2005) 0.91
A visual approach to providing prognostic information to parents of children with retinoblastoma. Psychooncology (2009) 0.91
Activity of the hypoxia-activated pro-drug TH-302 in hypoxic and perivascular regions of solid tumors and its potential to enhance therapeutic effects of chemotherapy. Int J Cancer (2013) 0.91
Enhanced drug delivery in rabbit VX2 tumours using thermosensitive liposomes and MRI-controlled focused ultrasound hyperthermia. Int J Hyperthermia (2012) 0.91
Hepatitis B virus DNA-positive, hepatitis B surface antigen-negative blood donations intercepted by anti-hepatitis B core antigen testing: the Canadian Blood Services experience. Transfusion (2007) 0.90
A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium. Invest New Drugs (2010) 0.89